Passage Bio doses first subject in Phase I/II dementia gene trial
Analysing the safety and tolerability of PBFT02 is the primary endpoint of the trial.

Analysing the safety and tolerability of PBFT02 is the primary endpoint of the trial.
According to the safety findings, PRV-002 was found to be safe and well tolerated in this cohort.
The geographic disparities behind early-onset dementia highlight the need to bridge the urban-rural divide.
ByThe trial will analyse the safety, tolerability and pharmacokinetics of various doses of OLX-07010 in healthy elderly subjects.
The Clinical Trials Arena team also investigate assets in radiculopathy, solid tumours, radicular pain, autoimmune disorders and inflammation.
ByKarXT offered a statistically significant and clinically meaningful 9.6-point decline in the PANSS total score versus placebo.
We also review assets in allergic rhinitis, anorexia, paroxysmal nocturnal haemoglobinuria, and polyomavirus infections.
ByMost currently approved ASD therapies are prescribed off-label, resulting in significant opportunity for developers in the market.
ByThank you for subscribing to Clinical Trials Arena